Item 2.05. Costs Associated with Exit or Disposal Activities.
On
As a result of the reduction in force, the Company estimates that it will incur
aggregate charges of approximately
Item 8.01. Other Events.
On
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 Press release issued bySage Therapeutics, Inc. onApril 7, 2020
Cautionary Note Regarding Forward-Looking Statements
The Company cautions you that statements included in this Current Report on Form
8-K that are not a description of historical facts are forward-looking
statements. In some cases, you can identify forward-looking statements because
they contain words such as "may," "will," "could," "should," "expects,"
"intends," "target,", "contemplates," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "potential," or "continue," or the negative
of these words or other similar terms or expressions that concern its
expectations, strategy, plans, prospects or intentions. Such statements include,
without limitation, statements regarding the Company's business strategy,
pipeline, structure and operations; the size, timing and impact of the Company's
reduction in workforce and related activities; the estimated charges and costs
expected to be incurred in connection with such reduction; and the projected
cost savings resulting from the restructuring and other cost-saving efforts. You
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. The Company's actual future results may
differ materially from its current expectations due to the risks and
uncertainties inherent in its business. These risks include, but are not limited
to: the risk that the Company may not realize cost savings from the
restructuring and other planned cost saving efforts at the levels it expects;
the risk that the costs associated with the restructuring may be higher than
expected and the timing of such costs may be different than the Company expects;
the risk that internal and external costs required for the Company's ongoing and
planned activities, and the resulting impact on expense and use of cash, may be
higher than expected, including as a result of challenges that may be
encountered in the course of planned activities or related to the Company's
business; the risk that the spread of COVID-19 and related fears in the
--------------------------------------------------------------------------------
© Edgar Online, source